Skip to main content
Top
Published in: Clinical Research in Cardiology 10/2023

Open Access 06-07-2023 | Heart Failure | Original Paper

Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients

Authors: Christoph Roderburg, Sarah Krieg, Andreas Krieg, Sascha Vaghiri, Raphael Mohr, Marcel Konrad, Mark Luedde, Tom Luedde, Karel Kostev, Sven H. Loosen

Published in: Clinical Research in Cardiology | Issue 10/2023

Login to get access

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease. Its high mortality and morbidity are mainly caused by non-hepatic comorbidities and their clinical complications. Accumulating evidence suggests an association between NAFLD and heart failure (HF), but large-scale data analyses from Germany are scarce.

Methods

Using the Disease Analyzer database (IQVIA), this analysis retrospectively evaluated two cohorts of outpatients with and without NAFLD with respect to the cumulative incidence of HF as the primary outcome between January 2005 and December 2020. Cohorts were propensity score matched for sex, age, index year, yearly consultation frequency, and known risk factors for HF.

Results

A total of 173,966 patients were included in the analysis. Within 10 years of the index date, 13.2% vs. 10.0% of patients with and without NAFLD were newly diagnosed with HF (p < 0.001). This finding was supported by univariate Cox regression analysis in which NAFLD was found to be significantly associated with subsequent HF (Hazard Ratio (HR) 1.34, 95% Confidence Interval (CI) 1.28–1.39, p < 0.001). The association between NAFLD and HF was observed across all analysed age groups and as comparable between both men (HR 1.30, 95% CI 1.23–1.38; p < 0.001) and women (HR: 1.37, 95% CI 1.29–1.45; p < 0.001).

Conclusion

NAFLD is significantly associated with an increased cumulative incidence of HF, which, given its rapidly increasing global prevalence, could be crucial to further reduce its high mortality and morbidity. We recommend risk stratification within a multidisciplinary approach for NAFLD patients, including systematic prevention or early detection strategies for HF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y et al (2022) Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun 6:3393–3405PubMedPubMedCentralCrossRef Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y et al (2022) Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun 6:3393–3405PubMedPubMedCentralCrossRef
2.
go back to reference Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202–209PubMedCrossRef Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202–209PubMedCrossRef
3.
go back to reference Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904PubMedCrossRef Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904PubMedCrossRef
4.
go back to reference Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al (2019) Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol 17:2085-2092.e2081PubMedCrossRef Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al (2019) Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol 17:2085-2092.e2081PubMedCrossRef
5.
go back to reference Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69:2672–2682PubMedCrossRef Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69:2672–2682PubMedCrossRef
6.
go back to reference Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565PubMedCrossRef Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565PubMedCrossRef
7.
go back to reference Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153PubMedCrossRef Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153PubMedCrossRef
8.
go back to reference Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: jacc state-of-the-art review. J Am Coll Cardiol 73:948–963PubMedCrossRef Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: jacc state-of-the-art review. J Am Coll Cardiol 73:948–963PubMedCrossRef
9.
go back to reference Byrne CD, Targher G (2022) Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 24(Suppl 2):28–43PubMedCrossRef Byrne CD, Targher G (2022) Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 24(Suppl 2):28–43PubMedCrossRef
10.
go back to reference Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G (2022) Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol 79:180–191PubMedCrossRef Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G (2022) Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol 79:180–191PubMedCrossRef
11.
go back to reference Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG et al (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:903–913PubMedCrossRef Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG et al (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:903–913PubMedCrossRef
12.
go back to reference Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6:578–588PubMedCrossRef Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6:578–588PubMedCrossRef
13.
go back to reference Anstee QM, Mantovani A, Tilg H, Targher G (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15:425–439PubMedCrossRef Anstee QM, Mantovani A, Tilg H, Targher G (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15:425–439PubMedCrossRef
14.
go back to reference Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L et al (2019) The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol 70:1203–1213PubMedCrossRef Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L et al (2019) The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol 70:1203–1213PubMedCrossRef
15.
go back to reference Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD et al (2021) Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 31:3464–3473PubMedCrossRef Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD et al (2021) Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 31:3464–3473PubMedCrossRef
16.
go back to reference Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S et al (2022) Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies. Ther Adv Chronic Dis 13:20406223221119624PubMedPubMedCentralCrossRef Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S et al (2022) Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies. Ther Adv Chronic Dis 13:20406223221119624PubMedPubMedCentralCrossRef
17.
go back to reference Dunn MA, Behari J, Rogal SS, O’Connell MR, Furlan A, Aghayev A et al (2013) Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver Int 33:1575–1582PubMedCrossRef Dunn MA, Behari J, Rogal SS, O’Connell MR, Furlan A, Aghayev A et al (2013) Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver Int 33:1575–1582PubMedCrossRef
18.
go back to reference Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56:459–466PubMedCrossRef Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56:459–466PubMedCrossRef
19.
go back to reference Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 2022. Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 2022.
20.
go back to reference Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569–582. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569–582.
21.
go back to reference Borges-Canha M, Neves JS, Libânio D, Von-Hafe M, Vale C, Araújo-Martins M et al (2019) Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine 66:467–476PubMedCrossRef Borges-Canha M, Neves JS, Libânio D, Von-Hafe M, Vale C, Araújo-Martins M et al (2019) Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine 66:467–476PubMedCrossRef
22.
go back to reference Chiu LS, Pedley A, Massaro JM, Benjamin EJ, Mitchell GF, McManus DD et al (2020) The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int 40:2445–2454PubMedPubMedCentralCrossRef Chiu LS, Pedley A, Massaro JM, Benjamin EJ, Mitchell GF, McManus DD et al (2020) The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int 40:2445–2454PubMedPubMedCentralCrossRef
23.
go back to reference VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME et al (2020) Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc 9:e014279PubMedPubMedCentralCrossRef VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME et al (2020) Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc 9:e014279PubMedPubMedCentralCrossRef
24.
go back to reference Zhou J, Bai L, Zhang XJ, Li H, Cai J (2021) Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications. Hepatology 74:2839–2847PubMedCrossRef Zhou J, Bai L, Zhang XJ, Li H, Cai J (2021) Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications. Hepatology 74:2839–2847PubMedCrossRef
25.
go back to reference Afolabi PR, Scorletti E, Smith DE, Almehmadi AA, Calder PC, Byrne CD (2018) The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the (13)C-ketoisocaproate breath test. J Breath Res 12:046002PubMedCrossRef Afolabi PR, Scorletti E, Smith DE, Almehmadi AA, Calder PC, Byrne CD (2018) The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the (13)C-ketoisocaproate breath test. J Breath Res 12:046002PubMedCrossRef
26.
go back to reference Aung LHH, Jumbo JCC, Wang Y, Li P (2021) Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: a concise review. Mol Ther Nucleic Acids 25:416–443PubMedPubMedCentralCrossRef Aung LHH, Jumbo JCC, Wang Y, Li P (2021) Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: a concise review. Mol Ther Nucleic Acids 25:416–443PubMedPubMedCentralCrossRef
27.
go back to reference Climent M, Viggiani G, Chen YW, Coulis G, Castaldi A. MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases. Int J Mol Sci 2020; 21. Climent M, Viggiani G, Chen YW, Coulis G, Castaldi A. MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases. Int J Mol Sci 2020; 21.
28.
go back to reference Patel VB, Zhong JC, Grant MB, Oudit GY (2016) Role of the ACE2/Angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ Res 118:1313–1326PubMedPubMedCentralCrossRef Patel VB, Zhong JC, Grant MB, Oudit GY (2016) Role of the ACE2/Angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ Res 118:1313–1326PubMedPubMedCentralCrossRef
29.
go back to reference Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264PubMedCrossRef Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264PubMedCrossRef
30.
go back to reference Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed
31.
go back to reference Jennison E, Byrne CD (2021) The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 27:22–43PubMedCrossRef Jennison E, Byrne CD (2021) The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 27:22–43PubMedCrossRef
32.
go back to reference Jacob JS, Ahmed A, Cholankeril G (2021) The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Infect Dis 34:477–482PubMedCrossRef Jacob JS, Ahmed A, Cholankeril G (2021) The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Infect Dis 34:477–482PubMedCrossRef
33.
go back to reference Zhao Y, Wang Z. Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease. J Lab Precis Med 2020; 5. Zhao Y, Wang Z. Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease. J Lab Precis Med 2020; 5.
34.
go back to reference Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A et al (2017) Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J 38:2948–2956PubMedCrossRef Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A et al (2017) Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J 38:2948–2956PubMedCrossRef
35.
go back to reference Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S et al (2020) Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 51:1305–1320PubMedPubMedCentralCrossRef Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S et al (2020) Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 51:1305–1320PubMedPubMedCentralCrossRef
36.
go back to reference Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465PubMedPubMedCentralCrossRef Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465PubMedPubMedCentralCrossRef
37.
go back to reference Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL et al (2015) Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61:515–525PubMedCrossRef Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL et al (2015) Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61:515–525PubMedCrossRef
38.
go back to reference Romero-Gómez M, Zelber-Sagi S, Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 67:829–846PubMedCrossRef Romero-Gómez M, Zelber-Sagi S, Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 67:829–846PubMedCrossRef
39.
go back to reference Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol 7:367–378PubMedCrossRef Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol 7:367–378PubMedCrossRef
40.
go back to reference Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262–276PubMedCrossRef Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262–276PubMedCrossRef
41.
go back to reference Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH (2021) Fatty liver index and development of cardiovascular disease: findings from the UK Biobank. Dig Dis Sci 66:2092–2100PubMedCrossRef Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH (2021) Fatty liver index and development of cardiovascular disease: findings from the UK Biobank. Dig Dis Sci 66:2092–2100PubMedCrossRef
42.
go back to reference Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF (2022) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 71:1867–1875PubMedCrossRef Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF (2022) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 71:1867–1875PubMedCrossRef
43.
go back to reference Roderburg C, Kostev K, Mertens A, Luedde T, Loosen SH. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer. Gut 2022. Roderburg C, Kostev K, Mertens A, Luedde T, Loosen SH. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer. Gut 2022.
44.
go back to reference Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM (2022) Impact of non-alcoholic fatty liver disease on metabolic comorbidities in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 130:172–177PubMedCrossRef Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM (2022) Impact of non-alcoholic fatty liver disease on metabolic comorbidities in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 130:172–177PubMedCrossRef
45.
go back to reference Roderburg C, Loosen SH, Jahn JK, Gänsbacher J, Luedde T, Kostev K et al (2021) Heart failure is associated with an increased incidence of cancer diagnoses. ESC Heart Fail 8:3628–3633PubMedPubMedCentralCrossRef Roderburg C, Loosen SH, Jahn JK, Gänsbacher J, Luedde T, Kostev K et al (2021) Heart failure is associated with an increased incidence of cancer diagnoses. ESC Heart Fail 8:3628–3633PubMedPubMedCentralCrossRef
46.
go back to reference Loosen SH, Roderburg C, Jahn JK, Joerdens M, Luedde T, Kostev K et al (2022) Heart failure and depression: a comparative analysis with different types of cancer. Eur J Prev Cardiol 29:e112–e114PubMedCrossRef Loosen SH, Roderburg C, Jahn JK, Joerdens M, Luedde T, Kostev K et al (2022) Heart failure and depression: a comparative analysis with different types of cancer. Eur J Prev Cardiol 29:e112–e114PubMedCrossRef
Metadata
Title
Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients
Authors
Christoph Roderburg
Sarah Krieg
Andreas Krieg
Sascha Vaghiri
Raphael Mohr
Marcel Konrad
Mark Luedde
Tom Luedde
Karel Kostev
Sven H. Loosen
Publication date
06-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 10/2023
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02250-z

Other articles of this Issue 10/2023

Clinical Research in Cardiology 10/2023 Go to the issue